Hepatobiliary Excretion PET/CT With 68Ga-TAoS-DAZA to Evaluate Bile Duct Patency

Clin Nucl Med. 2022 Jan 1;47(1):59-60. doi: 10.1097/RLU.0000000000003719.

Abstract

Tri-alkoxysalicyl-1,4-diazepan-6-amine (TAoS-DAZA) ligands, radiolabelled with 68Ga, have been proposed as PET/CT agents for depiction and quantification of hepatobiliary function and evaluation of bile excretion. In the presented case, a patient with hepatocellulary carcinoma underwent PET/CT with the TAoS-derivate 68Ga-tri-methoxysalicyl-(TMoS)-DAZA to determine the patency of intrahepatic and extrahepatic bile ducts, in particular of a stent in the common bile duct. The PET/CT was performed without complications. Evaluation of bile excretion over time was possible. 68Ga-TAoS-DAZA PET/CT may be an option for dynamic imaging of the excretory hepatic function to visualize the biliary tree and to rule out cholestasis.

MeSH terms

  • Bile Ducts
  • Biliary Tract* / diagnostic imaging
  • Hepatobiliary Elimination
  • Humans
  • Liver / diagnostic imaging
  • Liver / metabolism
  • Positron Emission Tomography Computed Tomography*